Skip to main content

Table 1 Patients characteristics

From: FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma

Characteristic

No. of patients (%)

No. of patients

101

  

Sex

 Male

83

 

(82)

 Female

18

 

(18)

Age, years

  Median (Range)

65

(32–82)

 

Pathology

  Clear cell

86

 

(85)

  Papillary

6

 

(6)

  Clear cell/Sarcomatoid

4

 

(4)

  Sarcomatoid

2

 

(2)

  Hemodialyssis

2

 

(2)

  Unclassified

1

 

(1)

Prior nephrectomy

  Yes

77

 

(76)

  No

24

 

(24)

Disease status

  Recurrent

61

 

(60)

   Metastatic

 

58

(57)

   Regional

 

3

(3)

  Stage IV

40

 

(40)

   Locoregional

 

4

(4)

   Metastatic

 

36

(36)

Prior systematic Therapy

  Yes

17

 

(17)

   IFN-α

 

9

 

   IFN-α/sorafenib

 

2

 

   Sorafenib

 

2

 

   Sunitinib

 

1

 

   S-1

 

1

 

   IFN-α/UFT

 

1

 

   Sorafenib/Temsirolimus

 

1

 

  No

84

 

83

  1. Abbreviation: IFN-α interferon-α
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us